Mode
Text Size
Log in / Sign up

Bempedoic acid 180 mg/day reduces LDL-C in Japanese patients with hypercholesterolemia over 52 weeksNew Cholesterol Option Works Well for Statin Intolerant Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider bempedoic acid as a lipid-lowering option in Japanese patients with statin issues, noting the single-arm design and lack of comparator.

This was a multicenter, open-label, single-arm Phase 3 long-term study conducted at 26 hospitals and clinics across Japan. The population included 130 Japanese patients aged 18 to 85 years with hypercholesterolemia who had previously failed to achieve lipid management targets due to inadequate response to statins or statin intolerance, or were rollover patients from the CLEAR-J trial. The intervention was bempedoic acid 180 mg/day, with no reported comparator.

Over a 52-week follow-up, the primary outcomes were long-term safety and efficacy. The main results showed that low-density lipoprotein-cholesterol (LDL-C) decreased by 21.6% in the overall population and by 25.3% in the newly enrolled group. At Week 52, 65.6% of patients achieved LDL-C target levels based on risk category.

Safety findings included treatment-emergent adverse events (TEAEs) in 83.8% of patients, with treatment-related TEAEs in 14.6%. Serious TEAEs occurred in 6.2%, and AEs leading to discontinuation occurred in 4.6%. The study reported that TEAEs were well tolerated with no major safety concerns and no new safety signals specific to the Japanese population.

Key limitations include the single-arm design without a comparator, which limits causal inference. The study was specific to a Japanese population, and generalizability to other groups is uncertain. Practice relevance was not reported, and funding or conflicts were not disclosed. These findings suggest bempedoic acid may be an option for lipid management in this population, but evidence from controlled trials is needed.

Why Finding Alternatives Matters

For years, doctors had limited choices for these patients. They often had to accept higher cholesterol levels. This new data suggests there is a viable path forward.

We need safe ways to manage heart health for everyone. Not every body reacts the same way to medication. Finding options is key to keeping people safe.

The Surprising Shift

Statins block the main assembly line in your liver. They stop the factory from making too much cholesterol. But this new drug blocks a different machine in the same building.

Think of it like a traffic jam on a highway. Statins close the main exit ramp. This new medicine closes a side road instead.

It stops the production without stopping the whole factory. This allows the body to keep working normally. It targets the problem without causing the usual trouble.

How the Drug Stops Cholesterol

Researchers tested this on 130 patients in Japan. Everyone took the medicine for 52 weeks. Most had tried statins before but could not continue.

The study looked at both new patients and those who stayed on treatment. They checked safety and how well it lowered numbers. This long look helps us understand real-world use.

The bad cholesterol dropped by about 22 percent. More than 60 percent of patients hit their health targets. Most side effects were mild and manageable.

Treatment-emergent side effects happened in about 84 percent of people. But only 15 percent were linked directly to the drug. Serious issues were rare and few people stopped taking it.

This does not mean this treatment is available yet.

Experts say this adds a valuable tool to the medical toolkit. It gives doctors another option when the first choice fails. Long-term safety is often the hardest part to prove.

Showing safety over a full year is a big step. It suggests the drug does not cause hidden problems over time. This builds confidence for doctors and patients alike.

Where This Fits In

You should not start this on your own. Talk to your doctor about your specific risks. They can decide if this is right for your body.

Your health history matters more than just the numbers. A doctor will look at your heart risk carefully. They will weigh the benefits against any potential risks.

Important Safety Details

This study only looked at patients in Japan. The group was relatively small compared to global trials. We need more data from other countries.

Genetics and diet can change how drugs work in different people. Results here are promising but not the final word. More testing ensures safety for a wider group.

More research will test this in different populations. Approval processes take time to ensure safety for everyone.

New drugs must prove they work in many settings. This study is a strong step in that direction. We wait for broader availability to see the full picture.

Study Details

Study typePhase3
Sample sizen = 130
EvidenceLevel 2
Follow-up12.0 mo
PublishedApr 2026
View Original Abstract ↓
AIMS: Bempedoic acid is an ATP citrate lyase (ACLY) inhibitor acting in the cholesterol biosynthesis pathway. This study evaluated long-term safety and efficacy of bempedoic acid 180 mg/day for 52 weeks in Japanese patients with hypercholesterolemia. METHODS: A multicenter, open-label, single-arm Phase 3 long-term study was conducted at 26 hospitals and clinics across Japan in patients aged 18 to 85 years. Newly enrolled patients had previously failed to achieve their lipid management targets because of inadequate response to statins or statin intolerance; rollover patients had completed the 12-week treatment period of a domestic Phase 3 confirmatory study (the CLEAR-J trial) and had not met the discontinuation criteria at Week 12. RESULTS: Bempedoic acid was administered to 130 patients. Treatment-emergent adverse events (TEAEs) occurred in 83.8%, treatment-related TEAEs in 14.6%, serious TEAEs in 6.2%, and AEs leading to discontinuation in 4.6%. None were severe. Between baseline and Week 52, low-density lipoprotein-cholesterol (LDL-C) decreased by 21.6% (overall population) and 25.3% (newly enrolled group), as observed in both statin response subgroups. LDL-C target levels based on risk category were achieved by 65.6% at Week 52 (overall population). Long-term efficacy was also demonstrated for non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein. CONCLUSIONS: Bempedoic acid 180 mg/day for 52 weeks was well tolerated in patients with hypercholesterolemia, with no major safety concerns. Serious AEs were infrequent, and no new safety signals specific to the Japanese population were observed. More than 60% of patients achieved and sustained their LDL-C target levels.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.